Expertise

Obtaining and maintaining a CLIA certificate is required for laboratories that perform high complexity testing in the United States. This article explains what CLIA oversight involves and how SpotitEarly complies with these standards in its CLIA-registered lab. By meeting federal requirements for quality and accuracy, SpotitEarly ensures its Laboratory Developed Tests are performed in a safe, reliable, and clinically valid manner.

SpotitEarly advances cancer detection through its innovation pipeline, combining AI, automation, and VOC biomarker research. Enhanced data collection improves predictive accuracy and automation scales testing capacity. Together, these breakthroughs pave the way for a more accurate, accessible, and scalable future in early diagnosis.

The cancer detection industry is undergoing rapid transformation, driven by demand for earlier diagnosis, multi-cancer technologies, and AI integration. This article explores the trends shaping the field, from liquid biopsy development to accessibility challenges, and highlights how SpotitEarly addresses these gaps. With a bio-AI breath test platform detecting VOCs at early stages, SpotitEarly combines accuracy, accessibility, and transparency to help lead the cancer detectio

SpotitEarly welcomed Dr. J. Leonard “Len” Lichtenfeld as its first Chief Medical Officer to help accelerate early cancer detection. This article outlines his career leadership at the American Cancer Society, his vision for catching cancer earlier, and his priorities at SpotitEarly: advancing rigorous clinical research, building partnerships across healthcare, and securing the resources to scale access to innovative, non‑invasive screening worldwide.

SpotitEarly’s LUCID bio-hybrid platform unites the natural sensitivity of trained detection dogs with the precision of artificial intelligence. This article explores how the system captures and analyzes breath samples, integrates biological and technological strengths, and delivers accurate, scalable early cancer detection. Learn how LUCID is redefining what’s possible in non-invasive cancer screening.

As SpotitEarly’s COO and co-founder, Udi Bobrovsky oversees the operational and strategic direction of the company’s early cancer detection platform. In this interview, he shares how his background in tech entrepreneurship and digital health drives the company’s mission, his approach to scaling a hybrid canine-AI screening system, and why he believes innovation and collaboration are key to transforming cancer detection globally.

At the heart of SpotitEarly’s innovation are its partnerships with leading hospitals and research institutions worldwide. This post explains how these clinical collaborations validate the accuracy of its breath-based screening method, integrate with existing protocols, and enhance early cancer detection efforts. Learn how SpotitEarly’s platform works alongside—not against—current standards for better, non-invasive diagnostics.